Australian-Singaporean regenerative medicine company Osteopore (ASX: OSX) has secured an exclusive licensing agreement with Accelerate for a pioneering Heparan Sulphate bioactive technology platform designed to accelerate bone and tissue regeneration.
Osteopore, a global leader in 3D-printed biomimetic and bioresorbable implants, has been collaborating with the Institute of Molecular and Cell Biology, A*STAR Research Entities, to integrate various Heparan Sulphate molecules into its proprietary implant technology.
The combination has the potential to significantly improve both the speed and quality of bone regeneration, potentially reducing recovery times, lowering complication rates, and enhancing overall patient outcomes.
In April 2024, Osteopore initiated a human clinical trial at the National University Hospital Singapore, combining Heparan Sulphate 3—a molecule targeting bone morphogenetic protein-2—with Osteopore’s approved implant for medial wedge opening high tibial osteotomy in up to 12 patients. The study is currently ongoing.
The 15-year exclusive license covers two families of Heparan Sulphate, including HS3, for all life science and medical applications across the United States, European Union, and China, encompassing patents, knowhow, upfront payments, royalties, and milestone-based payments.
While financial terms are confidential, the company does not anticipate a near-term material impact on operating results.
Osteopore CEO Dr Yujing Lim said the technology strengthens the company's position in regenerative medicine, offers a safer, more consistent alternative to current treatments, and aligns with the company's global expansion strategy as it begins the commercialisation process under regulatory requirements.
At the time of reporting, Osteopore's share price was $0.0060.